China Pharmaceutical University
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Dec 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 3, 2027The maintenance fee for Naphthalenesulfonamide compound, preparation method, and application (US 11,773,057) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 1 fee due Jul 7, 2027The maintenance fee for Pentapeptide associated with integrin receptor alpha vbeta3 (US 10,526,370) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Phenoxyacetic acid derivatives, preparation method thereof and use thereof as medicament (US 11,905,230) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Long-acting oxyntomodulin hybrid peptide, preparation method therefor, and application thereof (US 11,970,523) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction (US 10,639,289) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 22, 2026
- Sep 1 US 12,723,018 Cinnamoyl Amino Acid Compound and Use Thereof
- 1 term has ended since Aug 22, 2026
- Oct 14 US 8,859,527 Inclusion Complex of Deoxypodophyllotoxin of Cyclodextrin, Preparation Method, Use for Treatment of Cancer Thereof · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,085,022 | Inflammation-targeted neutrophil granulocyte drug delivery system and use thereof In force · USPTO record | In force | USPTO record | |
| US 10,526,370 | Pentapeptide associated with integrin receptor alpha vbeta3 In force (reinstated) · USPTO record | In force (reinstated) | USPTO record | |
| US 10,639,289 | Application of neuraminidase and inhibitors thereof in myocardial ischemia and myocardial infarction In force · USPTO record | In force | USPTO record | |
| US 11,905,230 | Phenoxyacetic acid derivatives, preparation method thereof and use thereof as medicament In force · USPTO record | In force | USPTO record | |
| US 11,479,545 | Compositions and methods for inhibiting phenyl triazole MLL1-WDR5 protein-protein interaction In force · USPTO record | In force | USPTO record | |
| US 12,054,478 | Compositions and methods for inhibiting phenyl triazole MLL1-WDR5 protein-protein interaction In force · USPTO record | In force | USPTO record | |
| US 11,572,359 | PARP/PI3K double-target inhibit containing pyridopyrimidine structure In force · USPTO record | In force | USPTO record | |
| US 11,504,385 | Proteolysis targeting chimeric molecule, preparation method, and application In force · USPTO record | In force | USPTO record | |
| US 12,310,944 | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof In force · USPTO record | In force | USPTO record | |
| US 12,226,476 | Helper epitope peptide and application thereof In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 22: 6 patents in force now held by others · 14 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
11 pending · 2 abandoned · 15 no status recorded